Slides
Page 1
Q3 & 9M FY2026 Results Presentation One of INDIA’S LARGEST Integrated Diagnostic Service Provider
Page 2
Disclaimer This presentation contains statements that are “forward-looking statements”, including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements pertaining to Krsnaa Diagnostics’ future business developments and economic performance. While these forward-looking statements indicate our assessment and future expectations concerning the development of our business, a number of risks, uncertainties and other unknown factors could cause actual developments and results to differ materially from our expectations. These factors include, but are not limited to, general market, macroeconomic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that could affect our business and financial performance. Krsnaa Diagnostics undertakes no obligation to publicly revise any forward-looking statements to reflect future/ likely events or circumstances. © Krsnaa Diagnostics Ltd. All Rights Reserved. Copyright 2026
Page 3
Krsnaa Diagnostics Limited
Page 4
190 CT/ MRI Centres 140 Pathology Labs 4,000+ Patient Collection Centres 18 States/UT Presence in India 81 Million+ Patients Served Since Inception Krsnaa Diagnostics At a Glance © Krsnaa Diagnostics Ltd. All Rights Reserved. Copyright 2026 Krsnaa Diagnostics is one of the fastest growing and Integrated diagnostic service provider which includes radiology, pathology and tele-radiology Provides quality and inclusive diagnostic services at affordable rates across various segments with a focus on Public Private Partnership model One of India’s largest NABH accredited tele-radiology reporting hub with inherent capability & capacity to process X-rays, CT scans and MRI scans, serving patients at remotest locations The workforce comprises 350+ radiologists, 120+ pathologists, and 3,000+ qualified professionals, including clinicians, technicians and operators
Page 5
Retail Dynamics 5 875 3,101 Q3 FY25 Q3 FY26 No. of Touch Points 22 177 Q3 FY25 Q3 FY26 Retail Revenue (mn) © Krsnaa Diagnostics Ltd. All Rights Reserved. Copyright 2026 “Y-o-Y Retail Business Revenue Increased By ~8x” 1% 10% Q3 FY25 Q3 FY26 Retail Revenue Contribution to Group Revenue 32% 28% 68% 72% Q3 FY25 Q3 FY26 B2B B2C Segment Retail Revenue Mix
Page 6
9MFY26 Financial Performance 6 Particulars 9M FY26 9M FY25 Growth Revenue 5,802 5,311 9% EBIDTA 1,600 1,416 13% EBIDTA Margin 28% 27% 92 bps PAT 597 569 5% PAT Margin 10% 11% (43 bps) Particulars 9M FY26 9M FY25 Growth EPS 18.2 17.3 5% No. of Patient Served 15 14.5 3% No. of Test performed 45.4 46.9 (3%) NABL Accreditation (Pathology lab) 57 49 16% NABH Accreditation (Radiology Centre) 49 26 88% © Krsnaa Diagnostics Ltd. All Rights Reserved. Copyright 2026 Note: 1. Financial results of the Company are best monitored on annual basis, as there is a certain level of cyclicity in business, and specific quarter performance may be impacted by specific events in that quarter 2. EBIDTA is excluding CSR & ESOP, INR in mn except EPS, NABL & NABH
Page 7
Q3FY26 Financial Performance 7 © Krsnaa Diagnostics Ltd. All Rights Reserved. Copyright 2026 Q3FY26 1,812 Q3FY25 1,745 Revenue from operation 4% Q3FY26 484 Q3FY25 465 Normalised EBIDTA 4% Q3FY26 168 Q3FY25 169 Normalised PAT 1% Q3FY26 27% Q3FY25 27% Normalised EBIDTA Margin Q3FY26 9% Q3FY25 10% Normalised PAT Margin Q3FY26 4.6 Q3FY25 4.6 No. of Patient Served 1% 44bps Note: 1. Financial results of the Company are best monitored on annual basis, as there is a certain level of cyclicity in business, and specific quarter performance may be impacted by specific events in that quarter 2. Normalized EBITDA excludes CSR, ESOP, and operational expenses incurred due to the ongoing implementation of the Rajasthan pathology project and the change in labour law aggregating Rs.10 mn. wherein revenue is not proportionate to these expenses. Normalized PAT excludes the above-mentioned expenses 3bps
Page 8
Launch of 1st Apulki Healthcare Hospital 8 © Krsnaa Diagnostics Ltd. All Rights Reserved. Copyright 2026 01 1st PPP Cancer and cardiac care hospital in india 05 Designed on same PPP principles that have scaled Krsnaa Diagnostics platform nationally 04 Approval to operationalise 4 more hospitals with capacity of 600 beds 03 All cancer treatment at CGHS rates under cash and carry model 02 150 beds in Association with Pune Municipal Corporation
Page 9
Facilities Under Apulki Healthcare Hospital 9 © Krsnaa Diagnostics Ltd. All Rights Reserved. Copyright 2026 160 Slice Cardiac CT LINAC PET CT
Page 10
Facilities Under Apulki Healthcare Hospital 10 © Krsnaa Diagnostics Ltd. All Rights Reserved. Copyright 2026 Dexa X-Ray Mammography
Page 11
Q3 FY26 – Centre Growth 11 139 149 Q3 FY25 Q3 FY26 CT Centre 39 41 Q3 FY25 Q3 FY26 114 114 Q3 FY25 Q3 FY26 MRI Centre 3,544 4,034 Q3 FY25 Q3 FY26 Satellite Lab Collection Centres 6 26 Q3 FY25 Q3 FY26 Reference Lab 1,434 1,501 Q3 FY25 Q3 FY26 Tele- Radiology Centre Upon completion of our existing order book, we will have 200+ CT/MRI centres, cementing our position as one of Asia’s Largest Radiology Players. The Rajasthan project will grow our network to 49 Reference Labs, 249 Satellite Labs & 5,000+ Collection Centres — making us India’s Deeply Rooted and Widely Accessible Pathology Service Provider. © Krsnaa Diagnostics Ltd. All Rights Reserved. Copyright 2026
Page 12
Competitive Advantages
Page 13
Driving Excellence Through Quality- INDIA’S 1ST © Krsnaa Diagnostics Ltd. All Rights Reserved. Copyright 2026 13 ACR Recognized Company NABH Accredited Tele- Radiology Hub CAP Accredited Lab at Government Facility Service Excellence Pioneers of Indian Diagnostic Industry
Page 14
Driving Excellence Through Quality © Krsnaa Diagnostics Ltd. All Rights Reserved. Copyright 2026 14 We are committed to delivering superior quality as our benchmark and proudly served ~4.6 mn patients in Q3 FY26, driven by our continuous focus on excellence. National Accreditation for Board of testing's & Calibration Laboratories 57 National Accreditation Board for Hospitals & Healthcare Providers 49 Quality Multiplied: The Power of 100+ Accreditations
Page 15
Building India’s National Diagnostics Infrastructure © Krsnaa Diagnostics Ltd. All Rights Reserved. Copyright 2026 15 The only listed company in PPP (Public Private Partnership) space with bid win ratio of 75%+ 18 states and union territories with penetration till tier-II and tier-III towns ~81 Mn+ patients served since inception Integrated diagnostic services available for 24/7 and 365 days, Radiology, Pathology, and Teleradiology Quality diagnostic services at most affordable prices (50- 70% lower than the peers) Operationalizing retail presence in 4 states Krsnaa has redefined what’s possible in diagnostics — proving that we can deliver radiology services at prices up to 50-70% lower than market, in a capital-intensive business, and still generate margins at par with the industry’s best. This isn’t a low-price government contract story — it’s a high-efficiency, high-impact model built to scale.
Page 16
Our Pricing - “Everyone Can Afford” © Krsnaa Diagnostics Ltd. All Rights Reserved. Copyright 2026 16 By offering services at over 50-70% below market rates, Krsnaa Diagnostics is expanding access to millions across India — and still growing faster than the industry, proving that scale, efficiency, and impact can go hand in hand. Segment Test Competition 1 Competition 2 Competition 3 Krsnaa % lower from competitors Radiology CT Brain 4,500 4,500 3,500 880 (75)% Radiology MRI Brain 8,000 8,250 7,000 1,340 (81)% Pathology CBC 250 250 200 37 (82)% Pathology Blood Sugar 85 80 70 20 (71)% Pathology Thyroid 500 550 550 55 (90)% Pathology Vitamin D 1,500 1,250 1,450 153 (89)% Pathology Vitamin B12 1,000 1,100 1,300 69 (95)% Pathology HbA1C 550 440 400 49 (88)% Note: Amounts are in INR. Above mentioned examples from our comprehensive test lists for illustration purpose only and referenced from publicly available information
Page 17
Presence - PAN India © Krsnaa Diagnostics Ltd. All Rights Reserved. Copyright 2026 17 Well Diversified Regional Revenue Mix 34% 12% 42% 12% West South North East Q3 FY26 India map for representation only, not to scale
Page 18
Financial Performance
Page 19
Consolidated Financial Performance © Krsnaa Diagnostics Ltd. All Rights Reserved. Copyright 2026 19 Particulars 9M FY 26 Q3 FY 25 Q3 FY 26 Q2 FY 26 9M FY 25 In mn Amount % Amount % Amount % Amount % Amount % Revenue from operations 1,812 1,745 2,060 5,802 5,311 Expenses Cost of Material Consumed 391 22% 399 23% 481 23% 1,347 23% 1,277 24% Employee benefits expense 356 20% 348 20% 348 17% 1,053 18% 1,008 19% Fees to hospitals and others 150 8% 136 8% 170 8% 474 8% 433 8% Other expenses 440 24% 397 23% 459 22% 1,327 23% 1,177 22% Total Expenses 1,337 74% 1,280 73% 1,458 71% 4,201 72% 3,895 73% Share of Profit/ (loss) of Associate (1) 0% - - 0.1 - (1) 0% - - EBITDA Before CSR & ESOP 474 26% 466 27% 602 29% 1,600 28% 1,416 27% CSR and ESOP 10 1% 15 1% 10 1% 31 1% 45 1% EBITDA 464 26% 451 26% 592 29% 1,569 27% 1,371 26% Less: Finance costs 78 4% 61 4% 82 4% 223 4% 178 3% Less: Depreciation 227 13% 227 13% 236 11% 679 12% 664 13% Add: Other income 38 2% 92 5% 42 2% 119 2% 211 4% PBT 197 11% 255 15% 316 15% 786 14% 741 14% Tax 44 2% 61 4% 77 4% 190 3% 172 3% PAT 152 8% 194 11% 239 12% 597 10% 569 11%
Page 20
Krsnaa Diagnostics Vivek Jain, Head- Investor Relations head.investor@krsnaa.in Contact: +91 74107 00645 https://krsnaadiagnostics.com For further information please contact